Plasma eicosanoid profile in plasmodium vivax malaria: clinical analysis and impacts of self-medication
Carregando...
Data
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
The participation of cytokines and chemokines in Plasmodium vivax malaria (Pv-malaria)
activates the immune response and thus causes the production of several inflammatory
mediators. This process is already well-established, but little is known about eicosanoids
in malaria physiopathology, especially in regards to inflammation and immunity. Malaria
is an acute febrile syndrome similar to any other less important infectious disease
and people may self-medicate with any anti-inflammatory drugs in order to cease the
recurrent symptoms of the disease. Based on this information, the study describes
the eicosanoid profile and its possible influence on the production of cytokines
and chemokines in P. vivax infections. In addition, we investigated the influence of
self-medication with anti-inflammatory drugs in this immune profile. Twenty-three patients
were included in the study, with or without self-medication by anti-inflammatory drugs
prior to diagnosis. A total 12 individuals were selected for the control group. Eicosanoid
profiles were quantified by HPLC-MS/MS, and cytokines and chemokines by flow
cytometry and ELISA. The Pv-malaria infection significantly reduces the production of
several lipid mediators, and its action is increased by self-medication. We observed
that the eicosanoids we found derive from the lipoxygenase and cyclooxygenase
pathways, and present positive and negative correlations with chemokines and cytokines
in the follow-up of patients. Our data suggest that self-medication may interfere in
the immunological characteristics in P. vivax infection and may modify the follow-up of
the disease.
Descrição
Palavras-chave
Citação
ABREU-FILHO, Péricles Gama et al. Plasma eicosanoid profile in plasmodium vivax malaria: clinical analysis and impacts of self-medication. Frontiers in Immunology, Lausanne, v. 10, e 2141, 2019. DOI: 10.3389/fimmu.2019.02141. Disponível em: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.02141/full. Acesso em: 29 jan. 2025.